Splenomegaly: Difference between revisions

Jump to navigation Jump to search
Line 584: Line 584:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! rowspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]]
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]]
! align="center" style="background:#DCDCDC;" |[[Hepatitis]]
! align="center" style="background:#DCDCDC;" |[[Hepatitis]]
Line 595: Line 595:
* Close contact
* Close contact
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 602: Line 602:
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Lymphadenopathy]]
* [[Lymphadenopathy]]
Line 926: Line 926:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
|-
! colspan="2" |Disease
!Etiology
!Demography
!History
!Fever
!Fatigue
!Weight loss
!Abdominal pain
!Bleeding
!BP
!JVP
!Jaundice
!Ascites
!Other
!WBC
!Hb
!Plt
!Iron
!LFT
!PT/PTT
!BUN/Cr
!UA
!Histopathology
!Imaging
!Gold standard
!Associated findings
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation
Line 1,006: Line 1,033:
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Rash|Skin rash]]
* [[Rash|Skin rash]]
Line 1,043: Line 1,070:
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Pallor]]
* [[Pallor]]
Line 1,103: Line 1,130:
* Family history
* Family history
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 1,109: Line 1,136:
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↓

Revision as of 23:52, 29 September 2018

WikiDoc Resources for Splenomegaly

Articles

Most recent articles on Splenomegaly

Most cited articles on Splenomegaly

Review articles on Splenomegaly

Articles on Splenomegaly in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Splenomegaly

Images of Splenomegaly

Photos of Splenomegaly

Podcasts & MP3s on Splenomegaly

Videos on Splenomegaly

Evidence Based Medicine

Cochrane Collaboration on Splenomegaly

Bandolier on Splenomegaly

TRIP on Splenomegaly

Clinical Trials

Ongoing Trials on Splenomegaly at Clinical Trials.gov

Trial results on Splenomegaly

Clinical Trials on Splenomegaly at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Splenomegaly

NICE Guidance on Splenomegaly

NHS PRODIGY Guidance

FDA on Splenomegaly

CDC on Splenomegaly

Books

Books on Splenomegaly

News

Splenomegaly in the news

Be alerted to news on Splenomegaly

News trends on Splenomegaly

Commentary

Blogs on Splenomegaly

Definitions

Definitions of Splenomegaly

Patient Resources / Community

Patient resources on Splenomegaly

Discussion groups on Splenomegaly

Patient Handouts on Splenomegaly

Directions to Hospitals Treating Splenomegaly

Risk calculators and risk factors for Splenomegaly

Healthcare Provider Resources

Symptoms of Splenomegaly

Causes & Risk Factors for Splenomegaly

Diagnostic studies for Splenomegaly

Treatment of Splenomegaly

Continuing Medical Education (CME)

CME Programs on Splenomegaly

International

Splenomegaly en Espanol

Splenomegaly en Francais

Business

Splenomegaly in the Marketplace

Patents on Splenomegaly

Experimental / Informatics

List of terms related to Splenomegaly

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Gichoya Judy Wawira [2], Moi University School of Medicine

Synonyms and keywords: Spleen enlargement; enlarged spleen; spleen swelling

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Splenomegaly from Other Diseases

Category Disease Etiology Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs Lab Findings Imaging
Fever Fatigue Weight Abdominal pain Bleeding BP JVP Jaundice Ascites Other CBC Iron LFT PT/PTT BUN/Cr UA Histopathology
WBC Hb Plt
Congestive Cirrhosis[1] Any, more in elderly + ↑↓ + + Nl + + Nl Liver biopsy
Heart failure[2] Elderly + ↑↓ ± + Nl Nl NA Echocardiography
Thrombosis of portal, hepatic, or splenic veins[3] Any + + + + Nl ± + Nl NA Doppler ultrasonography
Malignancy Lymphoma[4] Any, most common malignant splenic tumor + + + + Nl Nl + High ferritin Nl Lymph node biopsy
Leukemia[5] Elderly, male>female + + + + Nl Nl ± + High ferritin Nl
  • Leukemic blasts
  • Leukoerythroblastic features
  • Giant platelets
NA Bone marrow examination + clinical manifestation
Polycythemia Vera[6] Mean age >60 years old
  • Positive family history
+ Nl + Nl Nl Nl to ↑ Nl to ↑ High ferritin Nl Nl Nl Nl
  • Elevated normochromic, normocytic RBCs
  • Thrombocytosis
  • Rarely immature cells
  • Leukoerythroblastic picture
NA WHO criteria for PV
Disease Etiology Demography History Fever Fatigue Weight loss Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Multiple myeloma[7] Any, more in adults + + + + Nl Nl + High ferritin Nl
  • Blast cells
Bone marrow examination
Essential thrombocythemia[8]
  • Acquired mutation of JAK2, CALR, or MPL
Mean age >60 years old, female > male ± + Nl + + Nl Nl ↑↑ Nl Nl Nl Nl Nl Bone marrow biopsy
Primary myelofibrosis[9] Mean age >60 years old, male> female + Nl + + Nl Nl + ↑/↓ Low iron Nl Nl Bone marrow biopsy
Primary splenic tumors[10] Rare
Metastatic solid tumors[11] Any, more in adults + + + + Nl ± ± Low iron, high ferritin
  • Blast cells
Biopsy
Category Disease Etiology Demography History Fever Fatigue Weight Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Infection Viral Hepatitis
  • Infection
  • Autoimmune
Any
  • High risk behaviors
  • Close contact
+ + + + Nl Nl + + Nl Clinical manifestation + lab tests
Infectious mononucleosis
  • EBV
Cytomegalovirus
Bacterial Salmonella
Brucella
Tuberculosis
Parasitic Malaria
Schistosomiasis
Toxoplasmosis
Kala-azar Visceral leishmaniasis
Infective endocarditis
Fungal
Disease Etiology Demography History Fever Fatigue Weight loss Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Inflammation Sarcoidosis Autoimmune disease, more in young African American women
  • Positive family history
+ + + + Nl Nl - - Nl Nl Nl Nl Nl NA Diagnosis of exclusion
Serum sickness
Systemic lupus erythematosus More in young females
  • Family history
+ + + + Nl to ↓ Nl + + Clinical findings + laboratory studies
  • Multi organ damage
Felty syndrome Rare autoimmune disease, more in females 50-70 years old + + + + Nl to ↓ Nl + + Nl Nl Nl Nl Nl Clinical findings + laboratory studies
Category Disease Etiology Demography History Fever Fatigue Weight loss Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Infiltrative Gaucher disease[12] Rare, mostly in children
  • Family history
- + + + Nl to ↓ Nl + + Nl Nl Clinical findings + laboratory studies
Niemann-Pick disease
Amyloidosis
Langerhans cell histiocytosis
Hemophagocytic lymphohistiocytosis
Rosai-Dorfman disease
Hematologic (hypersplenic) states Hemolytic anemia
Sickle cell disease
Granulocyte colony-stimulating factor

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Treatment

Case Studies

Case #1

Related Chapters

References

  1. Wu Z, Zhou J, Pankaj P, Peng B (December 2012). "Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity". Surg Endosc. 26 (12): 3557–64. doi:10.1007/s00464-012-2366-5. PMID 22710653.
  2. Gedela M, Khan M, Jonsson O (September 2015). "Heart Failure". S D Med. 68 (9): 403–5, 407–9. PMID 26489162.
  3. Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ (2012). "Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center". Arq Gastroenterol. 49 (1): 69–76. PMID 22481689.
  4. Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y (May 2015). "Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma". Hematology. 20 (4): 203–7. doi:10.1179/1607845414Y.0000000192. PMID 25131182.
  5. Quest GR, Johnston JB (December 2015). "Clinical features and diagnosis of hairy cell leukemia". Best Pract Res Clin Haematol. 28 (4): 180–92. doi:10.1016/j.beha.2015.10.017. PMID 26614896.
  6. Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH (March 2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur. J. Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
  7. Grieco A, Manna R, Mancini R, Gambassi G (April 1988). "Massive hepatomegaly following splenectomy for myeloid metaplasia". Am. J. Med. 84 (4): 797. PMID 3400674.
  8. Tefferi A, Barbui T (February 2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am. J. Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
  9. Cervantes F, Martinez-Trillos A (May 2013). "Myelofibrosis: an update on current pharmacotherapy and future directions". Expert Opin Pharmacother. 14 (7): 873–84. doi:10.1517/14656566.2013.783019. PMID 23514013.
  10. Adachi K, Ui M, Nojima H, Takada Y, Enatsu K (August 2011). "Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy". Am. J. Surg. 202 (2): e17–9. doi:10.1016/j.amjsurg.2010.10.002. PMID 21810495.
  11. Huprikar NA, Kurtz MT, Mount CA (October 2013). "Massive splenomegaly and lymphopenia: a unique case of obstructive shock". BMJ Case Rep. 2013. doi:10.1136/bcr-2013-201643. PMC 3822246. PMID 24172780.
  12. Ayto R, Hughes DA (2013). "Gaucher disease and myeloma". Crit Rev Oncog. 18 (3): 247–68. PMID 23510067.